Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Oxford Gene Technology expands next-generation sequencing line

By Brian Buntz | November 4, 2020

Oxford Gene Technology

[Image from Oxford Gene Technology]

Oxford Gene Technology (OGT) has expanded its SureSeq line of next-generation sequencing (NGS) panels to detect genetic variants associated with breast and ovarian cancer and myeloid disorders.

One of the offerings is a myeloid panel that can detect abnormalities in 70 genes associated with a range of diseases, including acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. The panel can detect clinically relevant single nucleotide variants and insertion-deletion mutations (indels) with a 1% variant allele frequency, according to the company.

“One of the key facets of our SureSeq NGS panel offering is our customisation programme, SureSeq myPanel, in this we collaborate with our customers to rapidly generate the content that they desire, often this is at the forefront of discovery and not always commercially available,” said Emma Shipstone, executive vice president marketing at OGT. “Once there is community consensus on desired content we have the ability to bring panel content previously developed and optimized to a broader market.”

In addition, a 7-gene breast and ovarian cancer panel targets genes commonly tied to breast and ovarian cancer, such as BRCA1 and BRCA2. The panel also can detect copy number variation, the disparity in the number of copies of genes among individuals tied to several cancers, OGT said. The full interrogation of BRCA genes conventionally has required multiple tests to identify indels, single nucleotide variants and copy number variations. The SureSeq breast cancer panel can identify such variations in a single test, according to the manufacturer.

The breast and ovarian cancer panel also may identify mutations related to ataxia-telangiectasia mutated (ATM) genes, tumor protein P53, checkpoint kinase 2 (CHEK2), partner and localizer of BRCA2 (PALB2) in addition to phosphatase and tensin homolog (PTEN). The panel can also detect copy number variations in single exons in addition to full gene deletions or duplications in these genes, the company said.


Filed Under: Drug Discovery, Genomics/Proteomics, Oncology
Tagged With: acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, next-generation sequencing, Oxford Gene Technology
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50